Autoimmune epilepsy: Clinical characteristics and response to immunotherapy

Archives of Neurology

Volumn 69, Issue 5, 2012, Pages 582-593

  Quek, Amy M L ^a   Britton, Jeffrey W ^a   McKeon, Andrew ^a   So, Elson ^a   Lennon, Vanda A ^a   Shin, Cheolsu ^a   Klein, Christopher J ^a   Watson, Robert E ^a   Kotsenas, Amy L ^a   Lagerlund, Terrence D ^a   Cascino, Gregory D ^a   Worrell, Gregory A ^a   Wirrell, Elaine C ^a   Nickels, Katherine C ^a   Aksamit, Allen J ^a   Noe, Katherine H ^b   Pittock, Sean J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; AUTOANTIBODY; CHOLINERGIC RECEPTOR; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; CONTACTIN; CYCLOPHOSPHAMIDE; GLUTAMATE DECARBOXYLASE 65; IMMUNOGLOBULIN; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL COMPLEX;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE EPILEPSY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPLEX PARTIAL SEIZURE; DISEASE DURATION; ELECTROENCEPHALOGRAM; ELECTROGRAPHIC SEIZURE; EPILEPSY; EPILEPTIC AURA; EPILEPTIC DISCHARGE; FEMALE; FOCAL EPILEPSY; GENERAL CONDITION IMPROVEMENT; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; ONSET AGE; PLASMAPHERESIS; PREVENTION AND CONTROL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SYMPTOMATOLOGY; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84860910567     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.2985     Document Type: Article

References (43)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342(5):314-319. (Pubitemid 30075244)
2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51(4):676-685.
3. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96-107. (Pubitemid 40962465)
4. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327-340. (Pubitemid 351380534)
5. Hoffmann LA, Jarius S, Pellkofer HL, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry. 2008;79(7):767-773. (Pubitemid 351914721)
6. Bien CG, Urbach H, Schramm J, et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology. 2007;69(12):1236-1244. (Pubitemid 47429024)
7. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127(pt 3):701-712. (Pubitemid 38295483)
8. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776-785.
9. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734-2748.
10. Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(pt 6):1138-1148. (Pubitemid 32510382)
11. Marnane M, Vincent A, Hutchinson M. New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin. J Neurol. 2008;255(10):1603-1604.
12. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010; 67(4):470-478.
13. Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004;62(7):1177-1182. (Pubitemid 38456513)
14. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146-154. (Pubitemid 32157990)
15. Pittock SJ, Yoshikawa H, Ahlskog JE, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006;81(9):1207-1214. (Pubitemid 44316286)
16. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131(pt 10):2553-2563.
17. Barajas RF, Collins DE, Cha S, Geschwind MD. Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia. 2010;51(3):473-477.
18. Majoie HJ, de Baets M, Renier W, Lang B, Vincent A. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res. 2006;71(2-3): 135-141. (Pubitemid 44419592)
19. Irani SR, Buckley C, Vincent A, et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology. 2008;71(20):1647-1648.
20. Liimatainen S, Peltola M, Sabater L, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia. 2010;51(5):760-767.
21. Peltola J, Kulmala P, Isojärvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology. 2000;55(1):46-50. (Pubitemid 30460996)
22. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892-900.
23. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7 (12):1091-1098.
24. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67-76.
25. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4):424-434.
26. Vincent A, Irani SR, Lang B. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol. 2010;23(2):144-150.
27. McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology. 2005;65(11):1730-1736.
28. Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr Opin Neurol. 2011;24(2): 146-153.
29. Kraichely RE, Farrugia G, Pittock SJ, Castell DO, Lennon VA. Neural autoantibody profile of primary achalasia. Dig Dis Sci. 2010;55(2):307-311.
30. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology. 2008;70(20):1883-1890. (Pubitemid 351684641)
31. Flanagan EP, McKeon A, Lennon VA, et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc. 2010;85(10): 881-897.
32. Bien CG, Elger CE. Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav. 2007;10(4):529-538. (Pubitemid 46768031)
33. Bien CG, Schulze-Bonhage A, Deckert M, et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology. 2000; 55(12):1823-1828. (Pubitemid 32103963)
34. Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol. 1997;41(2):238-246. (Pubitemid 27082105)
35. Barber PA, Anderson NE, Vincent A. Morvan's syndrome associated with voltage-gated K+ channel antibodies. Neurology. 2000;54(3):771-772. (Pubitemid 30082963)
36. Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 2001;50(1):73-78.
37. McKeon A, Marnane M, O'connell M, Stack JP, Kelly PJ, Lynch T. Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. Arch Neurol. 2007;64(10):1528-1530.
38. Kalachikov S, Evgrafov O, Ross B, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet. 2002;30(3):335-341.
39. Fukata Y, Lovero KL, Iwanaga T, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci USA. 2010; 107(8):3799-3804.
40. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.
41. Niehusmann P, Dalmau J, Rudlowski C, et al. Diagnostic value of N-methyl-Daspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol. 2009;66(4):458-464.
42. McKeon A, Lennon VA, Pittock SJ. Immunotherapy-responsive dementias and encephalopathies. Continuum. 2010;16(2):80-101.
43. Bien CG, Scheffer IE. Autoantibodies and epilepsy. Epilepsia. 2011;52(suppl 3): 18-22.